Screening for Antifungal Activity

  • John F. Ryley
  • Keith Barrett-Bee


The purpose of antifungal screening is not to define the therapeutic properties of an individual compound, but rather to indicate which of a large number of compounds or samples are worthy of further study. The purpose is simply to provide a YES/NO answer to the question, “Is there sufficient interaction between this sample and fungi to warrant further investigation?” The attempt is to eliminate those samples which are of no definite interest, rather than to be dogmatic about samples which may be of interest. One wishes to reduce the size of a batch of samples considerably, so that those which remain can be subject to more careful study. Screening is not testing a handful of compounds for activity; it is essentially playing the numbers game. If compounds identified as interesting by the screen subsequently prove to be of no value (false positives), that does not matter; it is important that the screen does not reject compounds which really are of interest (false negatives). Once the preliminary process of screening is complete, the few samples which have been identified as possibly of interest can be evaluated in more comprehensive tests to determine their real potential and limitations. It is important to recognize the distinction between screening and evaluation. Screening is the detection of potentially interesting activity; evaluation is the quantitation and characterization of that activity.


Antifungal Activity Antifungal Agent Synthetic Chemical Ergosterol Biosynthesis Chitin Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams, D.J., & G.W. Gooday. 1980. A rapid chitin synthase preparation for the assay of potential fungicides and insecticides. Biotech. Lett. 2:75–78.CrossRefGoogle Scholar
  2. 2.
    Baguley, B.C., G. Rommelle, J. Gruner, & W. Wehrli. 1979. Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. Eur. J. Biochem. 97:345–351.PubMedCrossRefGoogle Scholar
  3. 3.
    Ballou, C. 1976. Structure and biosynthesis of the mannan component of the yeast cell envelope. Adv. Microbial Physiol. 14:93–158.CrossRefGoogle Scholar
  4. 4.
    Ballou, L., R.E. Cohen, & C.E. Ballou. 1980. Saccharomyces cerevisiae mutants that make mannoproteins with a truncated carbohydrate outer chain. J. Biol. Chem. 255:5986–5991.PubMedGoogle Scholar
  5. 5.
    Baloch, R.I., & E.I. Mercer. 1987. Inhibition of sterol A8-’L7-isomerase and A“- reductase by fenpropimorph, tridemorph and fenpropidin in cell-free enzyme systems from Saccharomyces cerevisiae. Phytochemistry 26:663–668.CrossRefGoogle Scholar
  6. 6.
    Barrett-Bee, K.J., J. Lees, & W. Henderson. 1982. Variation in the activities of enzymes associated with cell wall metabolism during a growth cycle of Candida albicans. FEMS Microb. Lett. 15:275–278.CrossRefGoogle Scholar
  7. 7.
    Boyle, F.T. 1990. Drug discovery: a chemist’s approach, p. 3–29. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96, Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar
  8. 8.
    Boyle, F.T., J.F. Ryley, & R.G. Wilson. 1987. In vitro-in vivo correlations with azole antifungals, p. S1:31-S1:41. In R.A. Fromtling (ed.), Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. J.R. Prous Science Publishers, Barcelona.Google Scholar
  9. 9.
    Brian, P.W., P.J. Curtis, & H.G. Hemming. 1946. A substance causing abnormal development of fungal hyphae produced by Penicillium janczewskii Zal. I. Biological assays, production, and isolation of `Curling Factor’. Trans. Br. Mycol. Soc. 29:173–187.CrossRefGoogle Scholar
  10. 10.
    Debono, M., & R.S. Gordee. 1990. Drug discovery: Nature’s approach, p. 77–109. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96, Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar
  11. 11.
    Etienne, G., E. Armau, & G. Tiraby. 1990. A screening method for antifungal substances using Saccharomyces cerevisiae strains resistant to polyene macrolides. J. Antibiotics 43:199–206.CrossRefGoogle Scholar
  12. 12.
    Flint, O.P., & F.T. Boyle. Structure-teratogenicity relationships among antifungal triazoles, p. 231–249. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96, Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar
  13. 13.
    Gadebusch, H.H., & M.E. Valiant. 1988a. Controlling mycotic infections. U.K. Patent GB2197194.Google Scholar
  14. 14.
    Gadebusch, H.H., & M.E. Valiant, 1988b. Controlling mycotic infections. U.K. Patent GB2200550.Google Scholar
  15. 15.
    Gunji, S., K. Arima, & T. Beppu. 1983. Screening of antifungal antibiotics according to activities inducing morphological abnormalities. Agric. Biol. Chem. 47:2061–2069.CrossRefGoogle Scholar
  16. 16.
    Hector, R.F., & P.C. Braun. 1986. Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans. Antimicrob. Agents Chemother. 29:389–394.PubMedCrossRefGoogle Scholar
  17. 17.
    Hector, R.F., B.L. Zimmer, & D. Pappagianis. 1990. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob. Agents Chemother. 34: 587–593.PubMedCrossRefGoogle Scholar
  18. 18.
    Iwasa, T., E. Higashide, H. Yamamoto, & M. Shibata. 1971. Studies on validamycins, new antibiotics. II. Production and biological properties of validamycins A and B. J. Antibiot. 24:107–113.PubMedCrossRefGoogle Scholar
  19. 19.
    Jolidon, S., A.-M. Polak, P. Guerry, & P.G. Hartman. 1990. Inhibitors of 2,3oxidosqualene lanosterol-cyclase as potential antifungal agents. Biochem. Soc. Trans. 18:47–48.PubMedGoogle Scholar
  20. 20.
    Kerkenaar, A. 1990. Inhibition of the sterol Δ14-reductase and Δ8→ Δ7 isomerase in fungi. Biochem. Soc. Trans. 18:59–61.PubMedGoogle Scholar
  21. 21.
    Kerridge, D., & H. Vanden Bossche. 1990. Drug discovery: a biochemist’s approach, p. 31–76. In J.F. Ryley (ed.), Handbook of Experimental Chemotherapy, vol. 96, Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar
  22. 22.
    Kirsch, D.R., & M.H. Lai. 1986. A modified screen for the detection of cell wall-acting antifungal compounds. J. Antibiot. 39:1620–1622.PubMedCrossRefGoogle Scholar
  23. 23.
    Konishi, M., M. Nishio, K. Saitoh, T. Miyaki, T. Oki, & H. Kawaguchi. 1989. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J. Antibiot. 42:1749–1755.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakajima, T., & C.E. Ballou. 1974. Characterization of the carbohydrate fragments obtained from Saccharomyces cerevisiae mannan by alkaline degradation. J. Biol. Chem. 249:7679–7684.PubMedGoogle Scholar
  25. 25.
    Nakajima, T., & C.E. Ballou. 1975. Yeast manno-protein biosynthesis: solubilization and selective assay of four mannosyltransferases. Proc. Nat. Acad. Sci. USA 72:3912–3916.PubMedCrossRefGoogle Scholar
  26. 26.
    Oki, T., M. Hirano, K. Tomatsu, K. Numata, & H. Kamei. 1989. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities. J. Antibiot. 42:1756–1762.Google Scholar
  27. 27.
    Polak, A. 1988. Mode of action of morpholine derivatives. Ann. N.Y. Acad. Sci. 544:221–228.PubMedCrossRefGoogle Scholar
  28. 28.
    Polak, A. 1990. Mode of action studies, p. 153–182. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96. Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar
  29. 29.
    Richardson, K., K.W. Brammer, M.S. Marriott, & P.F. Troke. 1985. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob. Agents Chemother. 27:832–835.PubMedCrossRefGoogle Scholar
  30. 30.
    Ryley, J.F. 1990. Screening and evaluation in vivo, p. 129–147. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96. Chemotherapy of Fungal Diseases, Springer-Verlag, Heidelberg.Google Scholar
  31. 31.
    Ryley, J.F., & S. McGregor. 1988. A multi-infection model for antifungal screening in vivo. J. Antimicrob. Chemother. 22:353–358.PubMedCrossRefGoogle Scholar
  32. 32.
    Ryley, J.F., & W.G. Rathmell. 1984. Discovery of antifungal agents: in vitro and in vivo testing, p. 63–87. In A.P.J. Trinci & J.F. Ryley (ed.), Mode of Action of Antifungal Agents, British Mycological Society Symposium No. 9, Cambridge University Press.Google Scholar
  33. 33.
    Ryley, J.F., R.G. Wilson, M.B. Gravestock, & J.P. Poyser. 1981. Experimental approaches to antifungal chemotherapy. Adv. Pharmacol. Chemother. 18:49–176.PubMedCrossRefGoogle Scholar
  34. 34.
    Selitrennikoff, C.P. 1983. Use of a temperature-sensitive, protoplast-forming Neurospora crassa strain for the detection of antifungal antibiotics. Antimicrob. Agents Chemother. 23:757–765.PubMedCrossRefGoogle Scholar
  35. 35.
    Selitrennikoff, C.P., B.L. Lilley, & R. Zucker, 1981. Formation and regeneration of protoplasts derived from a temperature-sensitive osmotic strain of Neurospora crassa. Exp. Mycol. 5:155–161.CrossRefGoogle Scholar
  36. 36.
    Sud, I.J., & D.S. Feingold. 1985. Effect of ketoconazole in combination with other inhibitors of sterol synthesis on fungal growth. Antimicrob. Agents Chemother. 28:532–534.PubMedCrossRefGoogle Scholar
  37. 37.
    Urbina, J.A., K. Lazardi, T. Aguirre, M.M. Piras, & R. Piras. 1988. Antiproliferative synergism of the allylamine SF 86–327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32:1237–1242.PubMedCrossRefGoogle Scholar
  38. 38.
    Wilson, R.G., & J.F. Ryley. 1990. Screening and evaluation in vitro, p. 111–128. In J.F. Ryley (ed.), Handbook of Experimental Pharmacology, vol. 96, Chemotherapy of Fungal Diseases. Springer-Verlag, Heidelberg.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • John F. Ryley
  • Keith Barrett-Bee

There are no affiliations available

Personalised recommendations